SEC Comment Letter for RespireRx Pharmaceuticals Inc. (RSPI) (CIK 0000849636) — Aug 12, 2021
RespireRx Pharmaceuticals Inc. (RSPI) (CIK 0000849636)
Date: Aug. 12, 2021 · CIK: 0000849636 · Accession: 0000000000-21-009871
AI Filing Summary & Sentiment
File numbers found in text: 024-11602
Letter
United States securities and exchange commission logo August 12, 2021 Timothy Jones Chief Executive Officer RespireRx Pharmaceuticals Inc. 126 Valley Road, Suite C Glen Rock, NJ 07452 Re:RespireRx Pharmaceuticals Inc. Offering Statement on Form 1-A Filed August 9, 2021 File No. 024-11602 Dear Mr. Jones: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Elizabeth Diffley, Esq.
Show Raw Text
United States securities and exchange commission logo
August 12, 2021
Timothy Jones
Chief Executive Officer
RespireRx Pharmaceuticals Inc.
126 Valley Road, Suite C
Glen Rock, NJ 07452
Re:RespireRx Pharmaceuticals Inc.
Offering Statement on Form 1-A
Filed August 9, 2021
File No. 024-11602
Dear Mr. Jones:
This is to advise you that we do not intend to review your offering statement.
We will consider qualifying your offering statement at your request. If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257
of Regulation A requires you to file periodic and current reports, including a Form 1-K which
will be due within 120 calendar days after the end of the fiscal year covered by the report.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Elizabeth Diffley, Esq.